naltrexone and liraglutide

naltrexone has been researched along with liraglutide in 26 studies

Research

Studies (26)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	19 (73.08)	24.3611
2020's	7 (26.92)	2.80

Authors

Authors	Studies
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J	1
Nakazato, M; Ueno, H	1
Aldhoon-Hainerová, I; Hainer, V	1
Hainer, V	1
Aronne, LJ	1
Fujioka, K	1
Howland, RH	1
Bragg, R; Crannage, E	1
Megyeri, J; Nuffer, W; Trujillo, JM	1
Camilleri, M; Chandar, AK; Dulai, PS; Khera, R; Loomba, R; Murad, MH; Prokop, LJ; Singh, S; Wang, Z	1
Braverman-Panza, J; Fujioka, K	1
Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH	1
Curry, SA	1
Golden, A	1
Bersoux, S; Byun, TH; Chaliki, SS; Poole, KG	1
Nadolsky, KZ	1
Wilding, JPH	1
Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M	1
Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K	1
Capasso, A; De Biasio, V; Di Munzio, W; Foggia, G; Milano, W	1
Barrea, L; Colao, A; Laudisio, D; Muscogiuri, G; Pugliese, G; Savastano, S	1
Brown, SA; Izzy, M; Watt, KD	1
Lee, SY; Tak, YJ	1
Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS	1
Hill, A; Levi, J; Venter, F; Wang, J	1
Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K	1

Reviews

18 review(s) available for naltrexone and liraglutide

Article	Year
Recent advancements in drug treatment of obesity. Clinical medicine (London, England), 2012, Volume: 12, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss	2012
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2014
Tolerability and safety of the new anti-obesity medications. Drug safety, 2014, Volume: 37, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate	2014
Overview of new antiobesity drugs. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Evolving directions in obesity management. The Journal of family practice, 2014, Volume: 63, Issue:7 Suppl Topics: Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Forecasting; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Liraglutide; Naltrexone; Narcotic Antagonists; Obesity; Receptors, Glucagon	2014
Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2015
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. Journal of psychosocial nursing and mental health services, 2015, Volume: 53, Issue:6 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesity; Psychotropic Drugs; Weight Gain	2015
A Comparison of New Pharmacological Agents for the Treatment of Obesity. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 2016, Jun-14, Volume: 315, Issue:22 Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lactones; Liraglutide; Male; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Weight Loss	2016
Practical Use of Pharmacotherapy for Obesity. Gastroenterology, 2017, Volume: 152, Issue:7 Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain	2017
Current pharmacotherapies for obesity: A practical perspective. Journal of the American Association of Nurse Practitioners, 2017, Volume: 29, Issue:S1 Topics: Adult; Anti-Obesity Agents; Benzazepines; Female; Humans; Lactones; Liraglutide; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Risk Reduction Behavior; United States	2017
Pharmacotherapy for obesity: What you need to know. Cleveland Clinic journal of medicine, 2017, Volume: 84, Issue:12 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine	2017
Gender-related issues in the pharmacology of new anti-obesity drugs. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:3 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Liraglutide; Male; Naltrexone; Obesity; Patient Selection; Sex Factors; Topiramate; Treatment Outcome; Weight Loss	2019
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. Folia medica, 2018, Dec-01, Volume: 60, Issue:4 Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Liraglutide; Naltrexone; Obesity; Orlistat; Polycystic Ovary Syndrome; Weight Loss	2018
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:8 Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Precision Medicine; Weight Loss	2020
New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. Minerva endocrinologica, 2020, Volume: 45, Issue:2 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Endocrinology; Humans; Liraglutide; Naltrexone; Nutritional Sciences; Obesity	2020
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:5 Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical	2021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Current obesity reports, 2021, Volume: 10, Issue:1 Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2021

Other Studies

8 other study(ies) available for naltrexone and liraglutide

Article	Year
Review of pharmacotherapy options for the management of obesity. Journal of the American Association of Nurse Practitioners, 2016, Volume: 28, Issue:2 Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States	2016
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. The Journal of family practice, 2016, Volume: 65, Issue:7 Suppl Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Primary Health Care; Risk Factors; Treatment Outcome; Weight Loss	2016
Obesity Epidemic: Pharmaceutical Weight Loss. Rhode Island medical journal (2013), 2017, Mar-01, Volume: 100, Issue:2 Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss	2017
Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population. Military medicine, 2018, 03-01, Volume: 183, Issue:3-4 Topics: Alcohol Deterrents; Appetite Depressants; Benzazepines; Cohort Studies; Drug Therapy; Humans; Incretins; Liraglutide; Military Personnel; Naltrexone; Obesity; Phentermine; Retrospective Studies	2018
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. Clinical obesity, 2018, Volume: 8, Issue:3 Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans; Life Style; Liraglutide; Naltrexone; Obesity; Primary Health Care; Specialization; State Medicine; United Kingdom; Weight Loss; Weight Reduction Programs	2018
[Pharmacotherapy for obesity]. Nederlands tijdschrift voor geneeskunde, 2021, 01-19, Volume: 165 Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Humans; Hunger; Life Style; Liraglutide; Naltrexone; Obesity; Satiation; Treatment Outcome; Weight Loss	2021
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:5 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Health Care Costs; Health Services Accessibility; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate	2023
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:9 Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Liraglutide; Naltrexone; Obesity; Overweight; Peptides; Proglucagon; Weight Loss	2023